e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

46.65 +0.94 (+2.05%)

Streaming Delayed Price Updated: 2:38 PM EDT, Aug 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win ↗

July 17, 2026

Novo Nordisk is finally getting one up on its biggest rival.

Via The Motley Fool

3 High-Yield Dividend Stocks to Buy and Hold ↗

July 17, 2026

All three can be bought on the dip.

Via The Motley Fool

Topics Intellectual Property

This GLP-1 Stock Could Double by 2030. Here's Why ↗

July 16, 2026

Investors need to ask tough questions before initiating a position in this biotech company.

Via The Motley Fool

2 Beaten-Down GLP-1 Stocks to Buy on the Dip ↗

July 15, 2026

Don't wait until clinical milestones send their share prices soaring.

Via The Motley Fool

Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market? ↗

July 14, 2026

Eyes are on the rollout of Lilly's new weight loss pill.

Via The Motley Fool

3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026 ↗

July 11, 2026

This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.

Via The Motley Fool

Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗

July 11, 2026

There are good reasons to invest in Lilly and to hold off.

Via The Motley Fool

Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market? ↗

July 10, 2026

So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.

Via The Motley Fool

Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week ↗

July 10, 2026

An accelerated approval for Agios' key drug to treat sickle cell disease appears to be on the cards.

Via The Motley Fool

Is It Too Late to Buy Eli Lilly? ↗

July 08, 2026

The stock has soared 400% in recent years.

Via The Motley Fool

Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026 ↗

July 08, 2026

Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many people can finally get them.

Via The Motley Fool

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom ↗

July 07, 2026

Don't sleep on these medical device leaders.

Via The Motley Fool

Topics Supply Chain

3 Reasons to Buy Novo Nordisk Stock ↗

July 07, 2026

The stock is down, but it isn't out yet.

Via The Motley Fool

U.S. Healthcare Spending Just Hit $5.7 Trillion and Continues to Grow: 2 Stocks to Buy to Profit From the Trend ↗

July 07, 2026

Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks.

Via The Motley Fool

As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner ↗

July 06, 2026

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

Via MarketBeat

Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? ↗

July 06, 2026

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

Via The Motley Fool

Could Buying Eli Lilly Stock Today Set You Up for Life? (Hint: Yes.) ↗

July 06, 2026

Lilly offers investors safety and growth.

Via The Motley Fool

How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030? ↗

July 05, 2026

This biotech might have a bright future, but it'll need to survive against the incumbents to do so.

Via The Motley Fool

Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying ↗

July 04, 2026

The stock is known to soar on good news.

Via The Motley Fool

Here's Why Viking Therapeutics Stock Surged Higher in June ↗

July 03, 2026

Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.

Via The Motley Fool

2 Top Growth Stocks to Buy Right Now Without Hesitation ↗

June 29, 2026

These stocks are no-brainer buys.

Via The Motley Fool

Topics Economy

Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗

June 29, 2026

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Via The Motley Fool

Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now ↗

June 27, 2026

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

Via The Motley Fool

Topics Intellectual Property

Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly? ↗

June 26, 2026

Novo Nordisk offers dividend income and MASH upside versus Lilly's high‑growth obesity lead.

Via The Motley Fool

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right? ↗

June 25, 2026

Novo Nordisk is no longer the front-runner, but it's not out of the running, either.

Via The Motley Fool

The Artificial Intelligence Opportunity Beyond Big Tech: 3 Healthcare Stocks to Watch ↗

June 25, 2026

These companies' innovative qualities could help them get ahead of their peers in capitalizing on AI.

Via The Motley Fool

Topics Artificial Intelligence

2 Underrated Weight Loss Stocks to Buy and Hold ↗

June 23, 2026

They look well-positioned to grab a slice of the fast-growing anti-obesity market.

Via The Motley Fool

Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk ↗

June 22, 2026

Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.

Via The Motley Fool

Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock? ↗

June 20, 2026

Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen.

Via The Motley Fool

3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend ↗

June 20, 2026

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

Via MarketBeat

Topics ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy